  | |
TechnologyOverviewSea Run's platform technology is therapeutics from salmon plasma proteins. These proteins, primarily fibrinogen and thrombin, are safe and effective, and could transform the way CNS injuries are treated. Salmon can regenerate their spinal cord, and Sea Run has found that this capability results in part from the coagulation proteins fibrinogen and thrombin (fibrin). These proteins are similar enough to human fibrinogen and thrombin to be interchangeable in terms of polymerization, but differ slightly in amino acid sequence and glycosylation, resulting in unique properties. An obvious concern with salmon fibrin is an immune response in the patient. Therefore, Sea Run has sponsored numerous animal trials, all with the same result. Salmon proteins induce antibodies, but these antibodies do not cross-react with the host animal's protein, and there have been no adverse symptoms in recipient animals. Furthermore, other salmon proteins such as salmon calcitonin and protamine have a long and useful clinical history. Worldwide production of farmed salmon now exceeds a million metric tons annually. Therefore, millions of liters of blood with consistent quality are available from animals where genetics, nutrition, and environment are controlled or closely monitored. |
SolutionsOur focus is on salmon fibrin (SEA-STAT®CNS) as a solution for central nervous system injury. However, we have identified numerous other applications where salmon fibrin could provide unique benefits.
|